The landscape of diagnostic testing is undergoing a significant transformation, driven by the integration of artificial intelligence (AI) and machine learning (ML) into decentralized, rapid, and accessible sensor platforms for point-of-care testing (POCT). The COVID-19 pandemic has accelerated the shift from centralized laboratory testing but also catalyzed the development of next-generation POCT platforms that leverage ML to enhance the accuracy, sensitivity, and overall efficiency of point-of-care sensors. This Perspective explores how ML is being embedded into various POCT modalities, including lateral flow assays, vertical flow assays, nucleic acid amplification tests, and imaging-based sensors, illustrating their impact through different applications. We also discuss several challenges, such as regulatory hurdles, reliability, and privacy concerns, that must be overcome for the widespread adoption of ML-enhanced POCT in clinical settings and provide a comprehensive overview of the current state of ML-driven POCT technologies, highlighting their potential impact in the future of healthcare.
1 September 2013 in Journal of Colloid and Interface Science
Successful integration of point-of-care testing (POCT) into clinical settings requires improved assay sensitivity and precision to match laboratory standards. Here, we show how innovations in amplified biosensing, imaging, and data processing, coupled with deep learning, can help improve POCT. To demonstrate the performance of our approach, we present a rapid and cost-effective paper-based high-sensitivity vertical flow assay (hs-VFA) for quantitative measurement of cardiac troponin I (cTnI), a biomarker widely used for measuring acute cardiac damage and assessing cardiovascular risk. The hs-VFA includes a colorimetric paper-based sensor, a portable reader with time-lapse imaging, and computational algorithms for digital assay validation and outlier detection. Operating at the level of a rapid at-home test, the hs-VFA enabled the accurate quantification of cTnI using 50 μL of serum within 15 min per test and achieved a detection limit of 0.2 pg/mL, enabled by gold ion amplification chemistry and time-lapse imaging. It also achieved high precision with a coefficient of variation of <7% and a very large dynamic range, covering cTnI concentrations over 6 orders of magnitude, up to 100 ng/mL, satisfying clinical requirements. In blinded testing, this computational hs-VFA platform accurately quantified cTnI levels in patient samples and showed a strong correlation with the ground truth values obtained by a benchtop clinical analyzer. This nanoparticle amplification-based computational hs-VFA platform can democratize access to high-sensitivity point-of-care diagnostics and provide a cost-effective alternative to laboratory-based biomarker testing.
A plaque assay—the gold-standard method for measuring the concentration of replication-competent lytic virions—requires staining and usually more than 48 h of runtime. Here we show that lens-free holographic imaging and deep learning can be combined to expedite and automate the assay. The compact imaging device captures phase information label-free at a rate of approximately 0.32 gigapixels per hour per well, covers an area of about 30 × 30 mm2 and a 10-fold larger dynamic range of virus concentration than standard assays, and quantifies the infected area and the number of plaque-forming units. For the vesicular stomatitis virus, the automated plaque assay detected the first cell-lysing events caused by viral replication as early as 5 h after incubation, and in less than 20 h it detected plaque-forming units at rates higher than 90% at 100% specificity. Furthermore, it reduced the incubation time of the herpes simplex virus type 1 by about 48 h and that of the encephalomyocarditis virus by about 20 h. The stain-free assay should be amenable for use in virology research, vaccine development and clinical diagnosis.
In this experimental study, we developed lateral flow immunoassay strips for the detection of Escherichia coli. For labelling, gold nanoparticles were prepared and modified with a Raman label. As a result of this, not only colorimetric responses but also Raman responses were obtained from the same strips. The color and Raman intensities were employed for the quantitative determination of Escherichia coli. The employment of two different detection methods strengthens the quantitative determination of Escherichia coli by lateral flow immunoassay, which is mostly used for qualitative detection or sometimes the semi-quantitative determination of samples. After careful optimization and validation steps, the developed strips allowed the highly sensitive determination of Escherichia coli in water and urine samples.
Beta-hemolytic, Group A Streptococcus pyogenes (GAS) is a life-threating pathogen and the reason for prominent disease, pharyngitis. The conventional analysis of GAS, gold standard, takes 48 hours and the related rapid tests lack in accuracy and sensitivity. In this study, firstly, the efficiency of swab sampling, which is a must in the GAS detection, was discussed with the proposed surface-enhanced Raman spectroscopy (SERS)-based batch assay and each step was controlled by the plate-counting method. Secondly, SERS-based lateral flow immunoassay (LFIA) test strips were constructed and the variation in the SERS intensity of 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) was observed. Thus, a linear correlation was found with a R2 value of 0.9926 and the LOD was calculated to be 0.2 CFU mL−1 of GAS which could be counted as one cell. The combination of the gold standard with the LFIA-SERS technique enabled the fast and accurate pathogen detection. In addition, GAS was quantified with paper-based test strips up to 100 CFU ml−1 level of bacteria for the first time without any interference. Besides, this study was featured with the discussion of the whole cell and pretreated cell detection of pathogens with LFIAs. Therefore, this work enlightens the points that have never been discussed on pathogen detection with paper-based platforms.